Peginterferon Alfa-2A: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia), SMC (Scotland) and TLV (Sweden) recommended or restricted peginterferon alfa-2a, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 20.2 years separate the first record, 15 Mar 2006 at HAS (France), from the most recent, 11 May 2026 at SMC (Scotland).
HAS (France) changed its position: recommended on 5 Mar 2014, not recommended by 9 Jul 2025.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for peginterferon alfa-2a, 3 submissions were never made — an outcome set by the company rather than the assessor.
The file is active: 3 of 16 records date from 2023 or later.
Against its own class, peginterferon alfa-2a is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class L03A average 84%.
7 distinct indication wordings are recorded for peginterferon alfa-2a by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess peginterferon alfa-2a, on 15 Mar 2006; PHARMAC (New Zealand) did not open a file until 11 Mar 2022 — an unusually long tail of 16 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 11 years in total.
3 of the 6 agencies here assessed peginterferon alfa-2a more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for peginterferon alfa-2a.
The full ledger for peginterferon alfa-2a reads 5 other, 4 recommended, 3 non-submission and 3 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 11 May 2026 | Monotherapy in adults for the treatment of polycythaemia vera. | not recommended | source |
| HAS (France) | 9 Jul 2025 | Indication extension | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 11 Mar 2022 | myeloproliferative neoplasms | PTAC advice: No Formal Recommendation · decision reached | source |
| PBAC (Australia) | 2017 | Myeloproliferative neoplasms (MPN) | The PBAC recommended the change in listing for peginterferon alfa-2a from Authority Requir… | source |
| AWMSG (Wales) | 17 Apr 2013 | In combination with ribavirin for the treatment of chronic hepatitis C in treatment-naive children and adolescents five … | excluded, NICE appraised | source |
11 further decisions for peginterferon alfa-2a, across 4 agencies, are not shown here. They include the most recent record on file, 11 May 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- filgrastim — same ATC class L03A — Immunostimulants
- pegfilgrastim — same ATC class L03A — Immunostimulants
- interferon beta-1a — same ATC class L03A — Immunostimulants
- plerixafor — same ATC class L03A — Immunostimulants
- glatiramer — same ATC class L03A — Immunostimulants
- ropeginterferon alfa-2b — same ATC class L03A — Immunostimulants
Coverage: 16 decisions for peginterferon alfa-2a from 6 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class L03A — Immunostimulants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.